Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs

Drug and Chemical Toxicology

Volumn 28, Issue 2, 2005, Pages 177-186

  Kim, Eun Joo ^a   Seo, Joung Wook ^a   Hwang, Ji Yoon ^a   Han, Sang Seop ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Blood pressure; Heart rate; Itraconazole; QT interval; Sildenafil; Telemetry

Indexed keywords

ITRACONAZOLE; SILDENAFIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAM; HEART RATE; HEART RATE VARIABILITY; MALE; NONHUMAN; QT INTERVAL; SINGLE DRUG DOSE; TELEMETRY;

ANIMALIA; CANIS FAMILIARIS;

EID: 17644382667     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1081/DCT-52525     Document Type: Article

References (22)

1. Alpaslan, M., Onrat, E., Samli, M., Dincel, C. (2003). Sildenafil citrate dose not affect QT intervals and QT dispersion: an important observation for drug safety. Ann. Noninvasive Electrocardiol. 8(1):14-17.
2. Awan, G. M., Calderon, E., Dawood, G., Alpert, M. A. (2000). Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. Am. J. Med. Sci. 320(1):69-71.
3. Chiang, C. E., Luk, H. N., Wang, T. M., Ding, P. Y. (2002). Effects of sildenafil on cardiac repolarization. Cardiovasc. Res. 55(1):290-299.
4. (1998). FDA Information. Viagra Information, Pharmacology Reviews, Overview of Pharmacokinetics/Toxicokinetics of UK-92,480. FDA Drug Information, Available at http://www.fda.gov/cder/foi/nda/98/viagra/pharm_tox_pp_9 1_116.pdf.
5. (1998). FDA Reports. Summary of Reports of Death in Viagra Users Received from Marketing (Late March) through Mid-November 1998, Available at http://www.fda.gov/cder/consumerinfo/viagra/safety3.htm.
6. Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., Wicker, P. A. (1998). Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338(20):1397-1404.
7. Hahn, I. H., Hoffman, R. S. (2000). Aroused to atrial fibrillation. Am. J. Emerg. Med. 18(5):642.
8. Hayashi, K., Minezaki, K. K., Narukawa, M., Ookubo, M., Mitsuhashi, T., Shimada, K. (1999). Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient. Jpn. Heart J. 40(6):827-830.
9. Hyland, R., Roe, E. G., Jones, B. C., Smith, D. A. (2001). Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br. J. Clin. Pharmacol. 51(3):239-248.
10. Iwamoto, K., Ikeda, J., Nito, M., Kosaka, N., Ichikawa, S., Ohmori, K., Sakai, K. (2001). Effect of oxatomide, an antiallergic agent, on QT interval in dogs. Arzneimittel-Forschung 51(12):971-976.
11. Jackson, G., Benjamin, N., Jackson, N., Allen, M. J. (1999). Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol. 83(suppl. 5A):13C-20C.
12. Kloner, R. K., Brown, M. L., Prisant, L. M., Collins, M. (2001). Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am. J. Hypertens. 14(1):70-73.
13. Muirhead, G. J., Rance, D. J., Walker, D. K., Wastall, P. (2000a). Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br. J. Clin. Pharmacol. 53(suppl. 1):13S-20S.
14. Muirhead, G. J., Wulff, M. B., Fielding, A., Kleinermans, D., Buss, N. (2000b). Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. 50(2):99-107.
15. Muirhead, G. J., Wilner, K., Colburn, W., Haug-Pihale, G., Rouviex, B. (2002). The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br. J. Clin. Pharmacol. 53(suppl. 1):21S-30S.
16. Nichol, D. J., Muirhead, G. J., Harness, J. A. (2002). Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol. 53(suppl. 1):5S-12S.
17. Sugiyama, A., Satoh, Y., Shiina, H., Takahara, A., Yoneyama, M., Hashimoto, K. (2001). Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J. Cardiovasc. Pharmacol. 38(6):940-946.
18. Webb, D. J., Freestone, S., Allen, M. J., Muirhead, G. J. (1999). Sildenafil citrate and blood pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol. 83(5A):21C-28C.
19. Wilner, K., Laboy, L., LeBel, M. (2002). The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br. J. Clin. Pharmacol. 53(suppl. 1):31S-36S.
20. Wlaker, D. K., Ackland, M. J., James, G. C., Muirheda, G. J., Rance, D. J., Wastall, P., Wright, P. A. (1999). Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29(3):297-310.
21. Yoo, S. D., Kang, E., Shin, B. S., Jun, H., Lee, S. H., Lee, K. C., Lee, K. H. (2002). Interspecies comparison of the oral absorption of itraconazole in laboratory animals. Arch. Pharm. Res. 25(3):387-391.
22. Zusman, R. M., Morales, A., Glasser, D. B., Osterloh, I. H. (1999). Overall cardiovascular profile of sildenafil citrate. Am. J. Cardiol. 83(5A):35C-44C.